Clinical Cancer Research Folkman
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Filipits, M.
Right arrow Articles by Drach, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filipits, M.
Right arrow Articles by Drach, J.
Related Collections
Right arrowCommentary
Clinical Cancer Research Vol. 9, 820-826, February 2003
© 2003 American Association for Cancer Research

Molecular Oncology, Markers, Clinical Correlates

Low p27Kip1 Expression Is an Independent Adverse Prognostic Factor in Patients with Multiple Myeloma1

Martin Filipits2, Gudrun Pohl, Thomas Stranzl, Hannes Kaufmann, Jutta Ackermann, Heinz Gisslinger, Hildegard Greinix, Andreas Chott and Johannes Drach

Department of Medicine I, Clinical Division of Oncology [M. F., G. P., T. S., H. K., J. A., J. D.], Division of Hematology and Blood Coagulation [H. Gi.], Bone Marrow Transplantation Unit [H. Gr.], and Department of Clinical Pathology [A. C.], University of Vienna, A-1090 Vienna, Austria


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: To determine the clinical relevance of p27Kip1 in multiple myeloma (MM), we examined the relationship between p27Kip1 expression at diagnosis and clinical as well as laboratory parameters, including response to chemotherapy and overall survival in 74 previously untreated patients with MM.

Experimental Design: Expression of p27Kip1 was assessed by immunohistochemistry on formalin-fixed, paraffin-embedded bone marrow biopsies. p27Kip1 expression was classified as low (<=5% p27Kip1-positive myeloma cells) or high (>5% p27Kip1-positive myeloma cells).

Results: Low p27Kip1 expression was observed in 23 (31%) patients. The response rate to standard dose chemotherapy (including vincristine, doxorubicin, and dexamethasone induction before high-dose chemotherapy) was 70%, with no significant difference between patients with low or high p27Kip1 expression (83 versus 65%; P = 0.1). Kaplan-Meier analysis of all 74 patients revealed that patients with low p27Kip1 expression had a significantly shorter overall survival (median, 3.7 years versus 4.7 years; P = 0.03) than those with high p27Kip1 expression. Patients with high p27Kip1 expression receiving high-dose chemotherapy experienced prolonged overall survival as compared with those with low p27Kip1 expression (median not yet reached versus 2.9 years; P = 0.008). By multivariate Cox regression analyses, low p27Kip1(P = 0.03), deletion of chromosome 13q14 (P = 0.02), and ß2-microglobulin (P = 0.01) were identified as independent adverse prognostic factors for overall survival. According to the number of independent unfavorable prognostic factors present in each patient, low-risk, intermediate-risk, and high-risk patients with different overall survival times were defined (median overall survival, 6.3 versus 4.2 versus 1.8 years; P < 0.001).

Conclusions: Low p27Kip1 expression is an independent adverse prognostic factor in patients with MM. The proposed risk score might be useful for risk-adapted treatment in the future.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Deregulation of cell cycle control is a critical step in the development of human cancers and, therefore, knowledge of the expression of cell cycle regulatory proteins in tumor cells is essential for understanding tumor cell behavior and may be also important for predicting prognosis of cancer patients. Cell cycle progression from G1 to the S-phase of the cell cycle is closely regulated by the formation of cyclin/Cdk3 complexes (1) . Cdk activity is inhibited by Cdk inhibitory proteins including the Cip/Kip family members p21Waf1/Cip1, p27Kip1, and p57Kip2 (2 , 3) . These proteins interact with complexes containing cyclin D, E, and A (4, 5, 6) , and recent data suggest that they exert both positive and negative regulation of Cdk activity at G1-S transition (7, 8, 9) . Many putative functions have been attributed to p27Kip1, including potential tumor suppressor gene (10) , promoter of apoptosis (11 , 12) , role in cell differentiation (13 , 14) , safeguard against inflammatory injury (15) , and regulator of drug resistance (16) .

Low expression of p27Kip1 has been shown to be an important prognostic factor in various B-cell hematological malignancies (17, 18, 19, 20) , but little is known about the prognostic significance of p27Kip1 in MM. In this study, we therefore determined the clinical relevance of p27Kip1 expression in unselected patients with MM and established a new prognostic model that included standard prognostic factors and p27Kip1 status.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Patients.
Eighty-eight consecutive, newly diagnosed patients with MM who had been treated at our institution between 1992 and 2000 were studied. Bone marrow biopsies obtained for diagnostic purposes were used after having obtained informed consent according to institutional guidelines. Fourteen patients had to be excluded because of insufficient number of myeloma cells in the specimens. Main characteristics of the 74 evaluable patients and correlations with p27Kip1 status are summarized in Table 1Citation .


View this table:
[in this window]
[in a new window]

  		Table 1 p27Kip1 and characteristics of 74 patients with MM

 
In 47 patients, treatment consisted of standard dose chemotherapy, either a melphalan-based regimen (melphalan plus prednisone or vincristine, melphalan, cyclophosphamide, and prednisone with or without carmustine) in 36 patients or VAD in 11 patients. The remaining 27 patients were treated by high-dose chemotherapy, followed by either autologous (n = 24) or allogeneic (n = 3) stem cell transplantation. In the autologous group, high-dose melphalan was preceded by three to six cycles of VAD as induction chemotherapy and one cycle of high-dose cyclophosphamide (n = 19) or ifosfamide, epirubicin, and etoposide (n = 5) followed by granulocyte colony-stimulating factor and peripheral blood stem cell collection. High-dose melphalan consisted of melphalan 200 mg/m2 in 12 patients, melphalan 140 mg/m2 and total body irradiation in 9 patients, and three cycles of melphalan 100 mg/m2 in 3 patients. Patients receiving allogeneic stem cell grafts were also treated by VAD before transplantation. Four patients with stage I disease were treated with chemotherapy because of a symptomatic disease. Response to standard dose induction chemotherapy or high-dose chemotherapy was assessed according to published consensus criteria (21 , 22) .

Immunohistochemistry.
Sequential biopsy sections were stained according to Giemsa and immunostained for CD138 and p27Kip1. Among hematopoietic cells, CD138 is selectively expressed by normal and neoplastic plasma cells (23) , and delicate membrane staining for CD138 is achieved by immunohistochemistry. p27Kip1 immunostaining was performed on formalin-fixed, paraffin-embedded bone marrow biopsies as described previously (24) . CD138 immunostaining was done according to the instructions of the manufacturer.

Briefly, sections were deparaffinized and endogenous peroxidase activity was blocked by incubation in 0.06% hydrogen peroxide for 10 min at room temperature. After boiling for 10 min in 10 mM citrate buffer (pH 6.0) for antigen retrieval, the tissues were preincubated for 20 min in normal serum (1:50; Dako, Glostrup, Denmark) before a 60-min incubation with the p27Kip1 monoclonal antibody (clone 57, antibody used at 1.25 µg/ml; Transduction Laboratories, Lexington, KY) or with the CD138 monoclonal antibody (clone B-B4, dilution 1:40; Serotec Ltd., Oxford, United Kingdom). Antibody binding was detected by the avidin-biotin-peroxidase method. Bound peroxidase was developed with 3,3'-diaminobenzidine (Dako) in the case of p27Kip1 and with 3-amino-9-ethylcarbazole (Sigma, St. Louis, MO) in the case of CD138. The slides were counterstained with Mayer’s Hämalaun and mounted with Aquatex (Merck, Darmstadt, Germany). All of the washes were performed in PBS (pH 7.4).

Expression of p27Kip1 of small lymphocytes was used as internal positive control of immunostaining (25) . In addition, negative controls without the primary antibody were performed as described above. Staining of myeloma cells was examined independently by two observers without prior knowledge of the clinical outcome of the patients. Areas containing sheets of myeloma cells, as demonstrated by CD138 staining, were chosen for the evaluation of p27Kip1 immunoreactivity. At least 200 myeloma cells/case were evaluated and the result expressed as the percentage of p27Kip1 labeled nuclei. Discrepant cases were reassessed together by both investigators and a consensus was reached.

FISH.
Chromosome 13q14 was studied by FISH with a DNA probe specific for the retinoblastoma gene 1 locus as described previously (26) .

Statistical Analysis.
Associations of p27Kip1 expression with clinical as well as laboratory parameters were assessed by the {chi}2 test or Mann-Whitney U test. Spearman rank correlation coefficient rs was used as a measure of correlation between p27Kip1 and Ki-67 expression. Survival probabilities were calculated with the product limit method according to Kaplan-Meier (27) . Overall survival time was defined as the period between the time of diagnosis and the time of death. Survival times of patients still alive were censored with the date of last follow-up. Differences between survival curves were analyzed by the log-rank test. Cox proportional hazards regression models were used to assess the independent effects of p27Kip1 expression on survival (28) . All Ps are results of two-sided tests. The SPSS 10.0 statistical software (SPSS Inc., Chicago, IL) was used for calculations.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
p27Kip1 Expression in MM at Diagnosis.
p27Kip1 expression was immunohistochemically determined in 74 previously untreated patients with MM. p27Kip1 immunostaining was nuclear and ranged from 0 to 90% of the myeloma cells. An example for p27Kip1 immunohistochemistry is shown in Fig. 1Citation . Comparisons of p27Kip1 expression with clinical parameters, including response to chemotherapy, were performed with p27Kip1 expression as a dichotomized variable classified as low (<=5% p27Kip1-positive myeloma cells) or high (>5% p27Kip1-positive myeloma cells). Low p27Kip1 expression was observed in 23 (31%) patients.



View larger version (120K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. p27Kip1 and CD138 immunohistochemistry. Representative examples of p27Kip1 (A and C) and CD138 staining (B and D). p27Kip1 nuclear reactivity is observed in the majority of myeloma cells in (A) which strongly stain for CD138 in (B). A specimen with low p27Kip1 expression in (C) which again strongly stain for CD138 in (D). Original magnification: x60.

 
Correlation with Clinical and Laboratory Parameters.
The major clinical and laboratory findings of the patients grouped according to low or high p27Kip1 expression are summarized in Table 1Citation . Seventy-four patients were evaluable for analysis of clinical and laboratory parameters and follow-up data. Patients with low or high p27Kip1 expression did not differ significantly in age and sex, stage, immunglobulin subtype, percentage of bone marrow myeloma cells, creatinine, hemoglobin, ß2-microglobulin, C-reactive protein, lactate dehydrogenase, deletion of chromosome 13q14, and Ki-67 expression. It is of particular interest that we found no correlation of p27Kip1 expression with the proliferation marker Ki-67 (rs = -0.1, P = 0.4; Fig. 2Citation ).



View larger version (10K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Scatter plot showing the distribution of 27Kip1 and Ki-67 in patients with MM. No significant correlation was observed between p27Kip1 and Ki-67 staining in 50 MM patients (rs = -0.1; P = 0.4).

 
Response to Chemotherapy and Survival.
Response to standard dose induction chemotherapy (including VAD before high-dose treatment) was evaluated in 74 patients. The overall response rate was 70%. Patients with low p27Kip1 expression had a response rate of 83%, whereas in patients with high p27Kip1 expression the response rate was 65%, but this difference did not reach the level of statistical significance (P = 0.1). A similar result (80 versus 64%; P = 0.3) was observed when only patients receiving VAD chemotherapy (n = 38) were analyzed. Twenty-seven patients were again evaluated for response after high-dose chemotherapy. At this time point, the complete response rate (stringently defined as normal bone marrow and absence of the paraprotein by immunofixation) was 30%. The complete response rates were not significantly different between patients with low or high p27Kip1 expression (38 versus 26%; P = 0.7).

The median follow-up of the total study population was 3.9 years, and the maximum follow-up was 7.4 years. Thirty-four patients died (14 patients with low p27Kip1 expression, 20 patients with high p27Kip1 expression). High-dose treatment was equally distributed among patients with low and those with high p27Kip1 expression (35 versus 37%; P = 0.8). The median overall survival of all 74 patients was 4.2 years. Patients with low p27Kip1 expression had a significantly shorter overall survival than those with high p27Kip1 expression (Fig. 3)Citation . Kaplan-Meier estimate of the median overall survival was 3.7 years for patients with low p27Kip1 expression, whereas for patients with high p27Kip1 expression, it was 4.7 years (P = 0.03). In the subgroup of patients receiving high-dose chemotherapy, a similar difference in overall survival times was observed between patients with low or high p27Kip1 expression (median overall survival 2.9 years versus not reached; P = 0.008).



View larger version (15K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. p27Kip1 and overall survival. p27Kip1 expression was determined by immunohistochemistry and overall survival was estimated according to Kaplan-Meier in 74 patients. Survival data based on p27Kip1 expression are shown. The 23 patients with low p27Kip1 expression had a significantly shorter overall survival than the 51 patients with high p27Kip1 expression (P = 0.03). Statistical comparison between survival curves was done by the log-rank test.

 
Analysis of Prognostic Factors.
The clinical and laboratory parameters used in the univariate analyses were age, sex, stage, immunglobulin subtype, percentage of bone marrow myeloma cells, creatinine, hemoglobin, ß2-microglobulin, C-reactive protein, lactate dehydrogenase, deletion of chromosome 13q14, and Ki-67 expression. In the univariate Cox regression analysis, the only variables significantly associated with shorter overall survival were ß2-microglobulin (P = 0.004), deletion of chromosome 13q14 (P = 0.004), and low p27Kip1 expression (P = 0.03; Table 2Citation ). We performed a multivariate Cox regression analysis of prognostic factors that included the parameters statistically significant in the univariate analyses. In this analysis, ß2-microglobulin (P = 0.01), deletion of chromosome 13q14 (P = 0.02), and low p27Kip1 expression (P = 0.03) were identified as independent prognostic factor for poor overall survival (Table 2)Citation .


View this table:
[in this window]
[in a new window]

  		Table 2 Cox regression analysis for overall survival of patients with MM

 
On the basis of the results of the multivariate analysis, we used the three independent prognostic factors associated with poor clinical outcome [high ß2-microglobulin (>=3 mg/liter, median value), deletion of chromosome 13q14, and low p27Kip1 expression] to define a risk score. Dependent on the number of poor prognostic factors present in each patient, three groups of patients were defined. Low-risk patients (with no poor prognostic factors), intermediate-risk patients (one or two unfavorable prognostic factors), and high-risk patients (three unfavorable prognostic factors) had significantly different overall survival times (Fig. 4)Citation . The median overall survival of low-risk, intermediate-risk, and high-risk patients was 6.3, 4.2, and 1.8 years, respectively (P < 0.001; Fig. 4Citation ). In the subgroup of patients who received high-dose chemotherapy, this difference in overall survival between low, intermediate, and high-risk patients was again observed (median overall survival not yet reached, 4.7, and 2.8 years; P = 0.002). Of particular note, all 6 low-risk patients were still alive at the time of the analysis.



View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Risk factors. Overall survival depending on the number of unfavorable prognostic factors (high ß2-microglobulin, deletion of chromosome 13q14, and low p27Kip1 expression). Low-risk patients (absence of poor prognostic factors; n = 14) have a prolonged overall survival compared with intermediate-risk patients (one or two unfavorable prognostic factors; n = 48) or high-risk patients (three unfavorable prognostic factors; n = 12; P < 0.001).

 

   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
In this study, low p27Kip1 expression in myeloma cells of patients with MM was predictive for shortened overall survival. Multivariate analyses demonstrated that the effect of p27Kip1 expression was independent of ß2-microglobulin and deletion of chromosome 13q14. The impact of p27Kip1 expression on overall survival was seen in the total study population but also in patients receiving high-dose chemotherapy. In this subgroup, patients with high p27Kip1 expression experienced also prolonged overall survival as compared with those with low p27Kip1 expression. Thus, our data underline the importance of cell cycle regulators for clinical outcome of MM patients. We additionally defined a risk-score according to the number of adverse prognostic factors present in each patient that allowed us to discriminate patients with different overall survival. This risk-score is an extension to a previously published score that included only ß2-microglobulin and deletion of chromosome 13q14 (29) .

In a variety of tumors, an inverse relationship between p27Kip1 expression and proliferative capacity has been observed. However, distinct entities of B-cell malignancies appear to exhibit a pattern, where p27Kip1 expression and cellular proliferation are not correlated. This has been described for mantle cell lymphoma (20) and diffuse large B-cell lymphoma (19) . Results from this study suggest that there is no significant association between p27Kip1 expression and the Ki-67 growth fraction also in MM. Because of the retrospective nature of this study, we were unable to study the S-phase fraction by the plasma cell labeling index, but S-phase cells and the Ki-67 growth fraction are usually correlated in MM. Thus, at least in the cases with expression of both p27Kip1 and Ki-67, p27Kip1 may fail to inhibit cell cycle progression in MM cells. Alternatively, in MM, p27Kip1 may have biological functions apart from cell cycle regulation.

MM is presently an incurable disease, and a major reason for this fact is resistance of myeloma cells to anticancer drugs. Several drug resistance mechanisms have previously been studied for their clinical relevance in MM, including drug transport mechanisms (30 , 31) or an altered apoptosis (32) . The Cdk inhibitors p21Waf1 and p27Kip1 may represent a new class of drug resistance genes. It has been recently reported that adhesion of myeloma cell lines to fibronectin, a component of the extracellular matrix, protects cells from apoptosis initiated by anthracyclins or alkylating agents (33) . This adhesion also increased p27Kip1 levels, and this increase in p27Kip1 levels was causally related to induction of cell adhesion-mediated drug resistance (34) . Activation of specific cell adhesion molecules may play an important role in signal transduction that regulates p27Kip1 expression, resulting in the inhibition of drug-induced apoptosis. Although p27Kip1 expression was not significantly associated with response in our study, a higher overall response rate to standard dose chemotherapy and a higher complete response rate after high-dose chemotherapy was observed for patients with low p27Kip1 expression. However, progression-free survival tended to be longer in patients with high p27Kip1 expression as compared with patients with low p27Kip1 expression (median, 2.5 versus 1.4 years; P = 0.1). In the subgroup of patients treated with high-dose chemotherapy, progression-free survival was significantly longer in patients with high p27Kip1 expression than in patients with low p27Kip1 expression (median, 3.5 versus 2.3 years; P = 0.004).

It is of particular clinical interest that patients with poor outcome after high-dose chemotherapy can be identified by low p27Kip1 expression. High-dose melphalan followed by autologous stem cell transplantation has become standard of care for patients with MM. There is now increasing evidence that a subgroup of patients with favorable prognostic features, most notably absence of a chromosome 13 deletion, benefits most from this treatment approach (35 , 36) . According to the prognostic score reported in our present study, we were able to identify patients with prolonged survival after high-dose therapy. This favorable subgroup was characterized by high p27Kip1 expression, low ß2-microglobulin, and a normal chromosome 13q by FISH. On the other hand, patients with risk factors, including low p27Kip1 expression, experience poor outcome even after high-dose therapy, which implies that novel, innovative treatment strategies need to be developed for this group of MM patients with high-risk features.

Proteasome inhibitors represent a potential new anticancer therapy. These agents inhibit the degradation of multiubiquitinated target proteins, including p27Kip1 (37) . After treatment of transformed human fibroblasts with a proteasome inhibitor, p27Kip1 levels increased and apoptosis was induced (37) . Therefore, treatment of high-risk MM patients with a proteasome inhibitor may increase p27Kip1 levels and induce apoptosis in MM cells, resulting in improved outcome in these patients. Along this line, PS-341, which is a potent and selective inhibitor of the proteasome, was shown to inhibit proliferation and the growth of human MM cell lines and patient MM cells resistant to doxorubicin, mitoxantrone, melphalan, and dexamethasone (38) . PS-341 was also shown to have antitumor activity in some patients with chemotherapy refractory MM and is therefore additionally evaluated in ongoing clinical trials (39) . In our study, we defined a subgroup of high-risk patients despite intensive therapy who may benefit from this novel treatment strategy. However, this possibility needs to be proven in future studies.

In conclusion, low p27Kip1 expression is an independent unfavorable prognostic factor associated with poor clinical outcome in patients with MM. Thus, p27Kip1 and/or the proposed risk score may be useful for the selection of patients for specific treatments and modulation of p27Kip1 expression may be a potential therapeutic strategy to improve clinical outcome in patients with MM in the future.


   ACKNOWLEDGMENTS
 
We thank Ngoc-Anh Huynh for excellent technical assistance.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This study was supported by Jubiläumsfonds der Österreichischen Nationalbank Grant Project No. 7760 and the Interdisciplinary Cooperation Project of the Austrian Federal Ministry for Education, Science, and Culture. G. P. was supported by a Hertha Firnberg-Fellowship from the Fonds zur Förderung der wissenschaftlichen Forschung Grant Project No. T71-MED. Back

2 To whom requests for reprints should be addressed, at Clinical Division of Oncology, Department of Medicine I, University Hospital Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. Phone: 43-1-40400-4429; Fax: 43-1-40400-4451; E-mail: martin.filipits{at}akh-wien.ac.at Back

3 The abbreviations used are: Cdk, cyclin-dependent kinase; MM, multiple myeloma; VAD, vincristine, doxorubicin, and dexamethasone; FISH, fluorescence in situ hybridization. Back

Received 4/ 1/02; revised 8/ 8/02; accepted 8/20/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Sherr C. J. Cancer cell cycles. Science (Wash. DC), 274: 1672-1677, 1996.[Abstract/Free Full Text]
  2. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev., 9: 1149-1163, 1995.[Free Full Text]
  3. Morgan D. O. Principles of CDK regulation. Nature (Lond.), 374: 131-134, 1995.[CrossRef][Medline]
  4. Xiong Y., Hannon G. J., Zhang H., Casso D., Kobayashi R., Beach D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.[CrossRef][Medline]
  5. Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massagué J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.[CrossRef][Medline]
  6. Matsuoka S., Edwards M. C., Bai C., Parker S., Zhang P., Baldini A., Harper J. W., Elledge S. J. p57Kip2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.[Abstract/Free Full Text]
  7. LaBaer J., Garrett M. D., Stevenson L. F., Slingerland J. M., Sanduh C., Chou H. S., Fattaey A., Harlow E. New functional activities for the p21 family of CDK inhibitors. Genes Dev., 11: 847-862, 1997.[Abstract/Free Full Text]
  8. Cheng M., Olivier P., Diehl J. A., Fero M., Roussel M. F., Roberts J. M., Sherr C. J. The p21Cip1 and p27Kip1 CDK ’inhibitors’ are essential activators of cyclin D-dependent kinases in murine fibroblast. EMBO J., 18: 1571-1583, 1999.[CrossRef][Medline]
  9. Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev., 13: 1501-1512, 1999.[Free Full Text]
  10. Fero M. L., Randel E., Gurley K. E., Roberts J. M., Kemp C. J. The murine gene p27Kip1 is haplo-insufficient for tumor suppression. Nature (Lond.), 396: 177-180, 1998.[CrossRef][Medline]
  11. Katayose Y., Kim M., Rakkar A. N. S., Li Z., Cowan K. H., Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res., 57: 5441-5445, 1997.[Abstract/Free Full Text]
  12. Levkau B., Koyama H., Raines E. W., Clurman B. E., Herren B., Orth K., Roberts J. M., Ross R. Cleavage of p21cip1/waf1 and p27kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade. Mol. Cell, 1: 553-563, 1998.[CrossRef][Medline]
  13. Durand B., Gao F. B., Raff M. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation. EMBO J., 16: 306-317, 1997.[CrossRef][Medline]
  14. Onishi T., Hruska K. Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. Endocrinology, 138: 1995-2004, 1997.[Abstract/Free Full Text]
  15. Ophascharoensuk V., Fero M. L., Hughes J., Roberts J. M., Shankland S. J. The cyclin-dependent kinase inhibitor p27kip1 safeguards against inflammatory injury. Nat. Med., 4: 575-580, 1998.[CrossRef][Medline]
  16. St. Croix B., Flørenes V. A., Rak J. W., Flanagan M., Bhattacharya N., Slingerland J. M., Kerbel R. S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.[CrossRef][Medline]
  17. Erlanson M., Portin C., Linderholm B., Lindh J., Roos G., Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood, 92: 770-777, 1998.[Abstract/Free Full Text]
  18. Møller M. B., Skjødt K., Mortensen L. S., Pedersen N. T. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin’s lymphoma: independent prognostic value of p27Kip1. Br. J. Haematol., 105: 730-736, 1999.[CrossRef][Medline]
  19. Sáez A. I., Sánchez E., Sánchez-Beato M., Cruz M. A., Chacón I., Muñoz E., Camacho F. I., Martínez-Montero J. C., Mollejo M., García J. F., Piris M. A. p27KIP1 is abnormally expressed in diffuse large B-cell lymphomas and is associated with an adverse clinical outcome. Br. J. Cancer, 80: 1427-1434, 1999.[CrossRef][Medline]
  20. Chiarle R., Budel L. M., Skolnik J., Frizzera G., Chilosi M., Corato A., Pizzolo G., Magidson J., Montagnoli A., Pagano M., Maes B., De Wolf-Peeters C., Inghirami G. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95: 619-626, 2000.[Abstract/Free Full Text]
  21. Chronic Leukemia-Myeloma Task Force. Proposed guidelines for protocol studies: II. Plasma cell myeloma. Cancer Chemother. Rep., 4: 145-158, 1973.
  22. Blade J., Samson D., Reece D., Apperley J., Bjorkstrand B., Gahrton G., Gertz M., Giralt S., Jagannath S., Vesole D. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol., 102: 1115-1123, 1998.[CrossRef][Medline]
  23. Wijdenes J., Vooijs W. C., Clément C., Post J., Morard F., Vita N., Laurent P., Sun R-X., Klein B., Dore J-M. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol., 94: 318-323, 1996.[CrossRef][Medline]
  24. Filipits M., Jaeger U., Pohl G., Stranzl T., Simonitsch I., Kaider A., Skrabs C., Pirker R. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin. Cancer Res., 8: 729-733, 2002.[Abstract/Free Full Text]
  25. Catzavelos C., Bhattacharya N., Ung Y. C., Wilson J. A., Roncari L., Sandhu C., Shaw P., Yeger H., Morava-Protzner I., Kapusta L., Franssen E., Pritchard K. I., Slingerland J. M. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat. Med., 3: 227-230, 1997.[CrossRef][Medline]
  26. Zojer N., Königsberg R., Ackermann J., Fritz E., Dallinger S., Krömer E., Kaufmann H., Riedl L., Gisslinger H., Schreiber S., Heinz R., Ludwig H., Huber H., Drach J. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood, 95: 1925-1930, 2000.[Abstract/Free Full Text]
  27. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.[CrossRef]
  28. Cox D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-220, 1972.
  29. Königsberg R., Zojer N., Ackermann J., Krömer E., Kittler H., Fritz E., Kaufmann H., Nösslinger T., Riedl L., Gisslinger H., Jäger U., Simonitsch I., Heinz R., Ludwig H., Huber H., Drach J. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. J. Clin. Oncol., 18: 804-812, 2000.[Abstract/Free Full Text]
  30. Sonneveld P. Multidrug resistance in haematological malignancies. J. Intern. Med., 247: 521-534, 2000.[Medline]
  31. Filipits M., Drach J., Pohl G., Schuster J., Stranzl T., Ackermann J., Königsberg R., Kaufmann H., Gisslinger H., Huber H., Ludwig H., Pirker R. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin. Cancer Res., 5: 2426-2430, 1999.[Abstract/Free Full Text]
  32. Chauhan D., Anderson K. C. Apoptosis in multiple myeloma: therapeutic implications. Apoptosis, 6: 47-55, 2001.[CrossRef][Medline]
  33. Damiano J. S., Cress A. E., Hazlehurst L. A., Shtil A. A., Dalton W. S. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93: 1658-1667, 1999.[Abstract/Free Full Text]
  34. Hazlehurst L. A., Damiano J. S., Buyuksal I., Pledger W. J., Dalton W. S. Adhesion to fibronectin via ß1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 19: 4319-4327, 2000.[CrossRef][Medline]
  35. Desikan R., Barlogie B., Sawyer J., Ayers D., Tricot G., Badros A., Zangari M., Munshi N. C., Anaissie E., Spoon D., Siegel D., Jagannath S., Vesole D., Epstein J., Shaughnessy J., Fassas A., Lim S., Roberson P., Crowley J. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood, 95: 4008-4010, 2000.[Abstract/Free Full Text]
  36. Facon T., Avet-Loiseau H., Guillerm G., Moreau P., Geneviève F., Zandecki M., Laï J-L., Leleu X., Jouet J-P., Bauters F., Harousseau J-L., Bataille R., Mary J-Y. on behalf of the Intergroupe Francophone du Myélome (IFM). Chromosome 13 abnormalities identified by FISH analysis and serum 2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 15: 1566-1571, 2001.
  37. An B., Goldfarb R. H., Siman R., Dou Q. P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ., 5: 1062-1075, 1998.[CrossRef][Medline]
  38. Hideshima T., Richardson P., Chauhan D., Palombella V. J., Elliott P. J., Adams J., Anderson K. C. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res., 61: 3071-3076, 2001.[Abstract/Free Full Text]
  39. Richardson P. G., Berenson J., Irwin D., Jagannath S., Traynor A., Rajkumar V., Alsina M., Kuter D., Srkalovic G., Siegel D., Barlogie B., Alexanian R., Orlowski R., Esseltine D., Kauffman M., Adams J., Schenkein D. P., Anderson K. C. Phase II study of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy. Blood, 98: 774a 2001.

Commentary

Prognostic Factors in Multiple Myeloma: It’s in the Genes
P. Leif Bergsagel
Clin. Cancer Res. 2003 9: 533-534. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 BloodHome page
Q. Chen, W. Xie, D. J. Kuhn, P. M. Voorhees, A. Lopez-Girona, D. Mendy, L. G. Corral, V. P. Krenitsky, W. Xu, L. Moutouh-de Parseval, et al.
Targeting the p27 E3 ligase SCFSkp2 results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy
Blood, May 1, 2008; 111(9): 4690 - 4699.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
F. Zhan, S. Colla, X. Wu, B. Chen, J. P. Stewart, W. M. Kuehl, B. Barlogie, and J. D. Shaughnessy Jr
CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms
Blood, June 1, 2007; 109(11): 4995 - 5001.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Filipits, M.
Right arrow Articles by Drach, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Filipits, M.
Right arrow Articles by Drach, J.
Related Collections
Right arrowCommentary

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online